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ARTICLE
How Often Do Safety Signals Occur by Chance
in First-in-Human Trials?
Gemma L. Clayton1,∗, Asher D. Schachter3, Baldur Magnusson2, Yue Li2 and Laurence Colin3
Clinicians working on first-in-human clinical studies need to be able to judge whether safety signals observed on an investi-
gational drug were more likely to have occurred by chance or to have been caused by the drug. We retrospectively reviewed
84 Novartis studies including 1,234 healthy volunteers receiving placebo to determine the expected incidence of changes in
commonly measured laboratory parameters and vital signs, in the absence of any active agent. We calculated the frequency of
random incidence of safety signals, focusing on the liver, cardiovascular system, kidney, and pancreas. Using the liver enzyme
alanine aminotransferase (ALT) as an example, we illustrate how a predictive model can be used to determine the probability
of a given subject to experience an elevation of ALT above the upper limit of the normal range under placebo, conditional on
the characteristics of this subject and the study.
Clin Transl Sci (2018) 00, 1–6; doi:10.1111/cts.12558; published online on yyyy-mm-dd.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Little information is available in the literature on the
expected variations in laboratory values and vital signs in
a clinical study setting, when subjects receive placebo. A
few reviews havementioned unexpectedly high rates of ALT
elevations in subjects taking placebo, but were based on
small data sets and did not adjust for individual character-
istics.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ Our goal was to provide a tool for clinicians working on
first-in-human studies, to quantify whether safety signals
observed were likely the result of chance or the compound
under investigation.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ We provided reference incidence rates under placebo
for commonly measured safety parameters. We built a
predictive model for ALT elevations that can be used to
quantify precisely how likely an event is due to chance,
conditionally on the characteristics of the subject and the
study.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔ This work should help teams identify safety signals ear-
lier and with greater accuracy.
A report published in 2014 revealed that about half of all US
Food and Drug Administration (FDA) rejections and delayed
approvals in recent years were due, at least in part, to safety
deficiencies,1 with cardiovascular and hepatic issues being
the most common concerns. Quantitative tools that identify
and characterize safety issues earlier in the life cycle of inves-
tigational compounds would have a large impact on the effi-
ciency of drug development, since the most costly phases of
drug development are phase II and phase III.2 Yet early phase
studies often lack quantitative evaluations of safety data.
First-in-human (FIH) studies offer the first opportunity to
test ascending doses of a new treatment in healthy volun-
teers. The primary objective of these studies is to investigate
the safety and tolerability of a new drug. Due to the typi-
cally small sample sizes of cohorts, safety signals are often
difficult to interpret, particularly in the absence of a robust
placebo group. Previous attempts at quantifying the back-
ground rate of liver enzyme elevations in placebo-treated
1Bristol Medical School, Population Health Sciences, University of Bristol, U.K; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Institute for Biomedical Research,
Cambridge, Massachusetts, USA. ∗Correspondence: Gemma L Clayton (gemma.clayton@bristol.ac.uk)
Received 29 January 2018; accepted 30 March 2018; published online on yyyy-mm-dd. doi:10.1111/cts.12558
healthy individuals3,4 were limited by small data sets and
did not take into account the demographic and background
characteristics of the healthy volunteers in their estimation of
the incidence rates. For most other safety events, no refer-
ence rates are available at all.
METHODS
Description of the data
We retrospectively reviewed studies in the Novartis database
that involved healthy volunteers and were completed before
2016. All clinical studies included in this article were spon-
sored by Novartis and reviewed by an Institutional Review
Board (IRB). Of those, we excluded 67 studies that did not
involve placebo and 44 studies that used a crossover design.
There were 11 studies for which the laboratory and vital signs
data were not readily available. All the placebo data from the
remaining 77 studies were pooled. Among these 77 studies,
69 were single-escalation or multiple-escalation designs, of
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Table 1 Demographics of the placebo database
N = 1,234 subjects n %
Sex: Male (n, %) 1,017 82.4
Ethnicity (n, %):
White 662 53.6
Hispanic or Latino 259 21.0
Asian 141 11.4
Black or African American 125 10.1
Other 47 3.8
Continent (n, %):
America/Canada 707 57.3
Europe 399 32.3
Australia 40 3.2
Asia 88 7.1
Age (years) (Median, Q1-Q3)a 32 25–43
Height (cm) (Median, Q1-Q3), N = 1,212 175.0 168.2–181.0
Weight at baseline (kg) (Median, Q1-Q3) 77.1 68.0–85.8
aQ1 = first quartile (25th percentile), Q3 = third quartile (75th percentile). Age
ranged from a minimum of 18 to a maximum of 78 years. Height ranged from a
minimum of 143.8 to a maximum of 199.0 cm. Weight ranged from a minimum
of 47.7 to a maximum of 116.1 kg.
which 10 were conducted in Japanese subjects and one in a
Chinese subject. The number of placebo subjects per study
varied between 3 and 57, with a mean of 16.03 per study.
The number of postbaseline observations per study varied
between one and 18, with a mean of 5.65.
We selected the following routinely measured safety
parameters for our review:
 Liver safety: alanine aminotransferase (ALT), aspartate
aminotransferase (AST), bilirubin.
 Cardiovascular safety: the Fridericia-corrected QT inter-
val (QTcF), standing systolic blood pressure (SBP), heart
rate (HR).
 Renal safety: serum creatinine.
 Pancreatic safety: lipase, amylase.
While normal laboratory ranges are known for all of the
parameters listed above, incidences of randomly occurring
values outside of the normal ranges for healthy subjects
receiving placebo in the setting of a clinical study are not
known.
The pooled database included 1,234 subjects with avail-
able measurements in at least one of the categories above.
The demographic characteristics of the population are pre-
sented in Table 1.
We present the raw incidences of various safety events in
the pooled database and explain how these can be used to
give a preliminary assessment of whether signals observed
during the use of an investigational drug are in line with the
expected incidence with placebo.
A model that adjusts for potential study differences and
subject characteristics provides a more precise assessment.
We use the liver enzyme ALT (U/L) as an example to illustrate
the potential application of this method.
Demographic and background information included a sub-
ject’s age, gender, ethnicity, continent, height, weight, and
baseline value. Baseline ALT was taken postrandomization
and prior to the placebo being given. Due to differences
between assays used, the upper limit of the normal range
(ULN) varied slightly and we therefore normalized the ALT val-
ues by the corresponding ULN value and used ALT/ULN as
the response variable for modeling purposes. Histograms of
continuous covariates were produced to check for normal-
ity and potential outliers. Log transformation was applied to
baseline ALT and age. Baseline ALT was calculated in the
unit of ULN and then log transformed to obtain an approxi-
mately normally distributed variable. Age was also log trans-
formed for the same reason. Log transformation was initially
attempted for the number of samples; however, this did not
improve the model fit and therefore the original scale was
used to aid interpretation. Weight was approximately nor-
mally distributed and therefore no transformation was con-
sidered necessary. All variables were standardized to a scale
with a mean of 0 and standard deviation of 1. The standard-
ization was done via the typical approach, i.e., subtracting
the mean of the variable from each of the individual (subject)
values and dividing by the overall standard deviation.
Description of the model
We modeled the probability of a subject developing an
event of ALT > ULN at least once during a study. To
this end, we fitted a multilevel logistic regression model
as follows.5 For subject i in study j we define the event
yi = 1 if the subject had at least one ALT measurement
exceeding the ULN during the study. The probability of this
event was modeled as Bernoulli[logit−1(α j + Xiβ )], where
α j represents the study-specific intercept used to account
for between-trial variation, Xi is a vector of covariates
specific to subject i (including the number of postbase-
line samples for subject i), and β is a vector of covari-
ate parameters. The model was fitted in the Bayesian
framework using the following weakly informative priors:
α j = α + uj, with α ∼ Cauchy(0, 10), uj ∼ N(0, τ 2 ), τ ∼
Exponential(1), and β ∼ Cauchy(0, 2.5). Since a logistic
regression model was fit, model coefficient estimates are
reported as the log transformed odds ratios of the posterior
means.
The baseline covariates described in Table 1 were evalu-
ated for inclusion in the model, using a forward selection that
calculates the difference in deviance for nested models. The
model with the smallest expected log pointwise predictive
density was selected.6 Model fit was checked by comparing
posterior predictive distributions to observed values. Model
fitting was done using Stan7 via the R library (v. 3.4.1) RSta-
nArm (v. 2.15.3).8 No time-trend was observed in the longi-
tudinal data and hence a time slope was not included in the
abovemodel. Instead, the longitudinal aspect of the data was
taken into account by including the number of postbaseline
assessments as a covariate in the model.
The “virtual placebo twin”
From this model, we can derive the subject-specific proba-
bility of experiencing an event, conditionally on this subject’s
covariates. For subject i in our data set, we would condition
on the study-level effect α j, while for a new subject this
probability would be obtained by integrating over the study
effect distribution9,10 (see Supplementary Material for more
Clinical and Translational Science
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detail). We can also derive a marginal (population average)
probability of a subject to experience an event by averaging
over the distribution of covariates. Due to the nonlinearity of
the model, the conditional probability of a subject with mean
covariate values is not expected to match the population
mean marginal probability. In other terms, taking the mean
before or after the logit transformation will not yield the same
results, as it is always the case for generalized linear models
with a nonlinear link function. In this setting, because we
are mostly interested in predictions for specific subjects in
a new study (for whom we know the baseline covariates),
the conditional probability is of most interest. For a subject
receiving an active drug in a new study experiencing an
ALT > ULN event, we will produce the predicted probability
of this subject also experiencing this event had he/she
received placebo instead of active drug, based on the model
described above. We will call this prediction the probability of
a “virtual placebo twin” to experience the event. Whether or
not the virtual placebo twin is also likely to have experienced
an event will determine whether the investigational drug is
likely to have caused the event or not.
Finally, we can combine the individual subjects’ probabili-
ties to estimate the probability that at least one subject expe-
riences one event in a cohort of size n. This can be done by
using conditional probabilities (a different one for each sub-
ject) if subject-specific covariates are available, or marginal
probabilities (identical for each subject) if subject covariates
are not available.
RESULTS
The raw incidence of various safety signals in our pooled
database of healthy volunteers receiving placebo are shown
in Table 2, by target organ. This table can be used to
judge how frequently random safety findings occur in a
healthy population. For example, the table’s data indicate
that increases in heart rate (HR) by more than 20 beats per
minute from baseline occur in about 14.16% of healthy sub-
jects receiving placebo. Therefore, in a cohort of six sub-
jects, observing HR increases of this magnitude in two sub-
jects receiving active drug wouldn’t necessarily be a con-
cern, since it is not unlikely to happen in the same popu-
lation receiving placebo: the probability of observing at least
two subjects with an event in a cohort of six, if the event
truly occurs with a 14.16% probability, is 20% (from the bino-
mial distribution, see Table 3). On the other hand, eleva-
tions of amylase above 2 times the upper limit of normal only
occur in 0.33% of healthy subjects receiving placebo. In this
case, observing just one subject in a cohort of six subjects
with elevations of this magnitude raises concerns about the
investigational treatment, since this is unlikely to happen (2%
chance) under placebo (Table 3).
While these raw incidence rates are helpful in provid-
ing a quick assessment of the likelihood for a safety signal
to be caused by the active compound under investigation,
more accurate answers can be given with a model adjust-
ing for differences between study and individual subject
characteristics.
Using the event ALT > ULN as an example, the raw inci-
dence of elevations in healthy volunteers taking placebo is
6.24%, as shown in Table 2. However, this prediction varies
substantially across individuals. Following the model selec-
tion procedure described earlier, a logistic model of the prob-
ability of a subject to experience at least one ALT > ULN
event during the study was built, and the final covariates and
model coefficients are shown in Table 4.
The between-study variance is 1.20, which represents
27% of the residual variance. The impact of age and weight
on the probability of a subject developing an ALT elevation
above ULN during a study is small in magnitude, and perhaps
counterintuitively, is negative: increasing age and weight is
associatedwith reduced risk of a randomALT elevation under
placebo. Of note, including sex did not improve the model
significantly; however, this could be due in part to the fact
that 82% of the subjects in our pooled database were male.
The most important predictor of an event is ALT at baseline,
but the number of samples collected during the study also
influences the likelihood of observing an event. Therefore, as
highlighted in Figure 1a, subjects with baseline ALT close
to ULN and in studies with >8 samples taken have a much
higher probability of an ALT > ULN.
Figure 1a shows the distribution of individual predicted
probabilities of ALT > ULN for all subjects in the data set.
For a typical subject with average covariate values (base-
line ALT value of 21.5 U/L, ULN of 55 U/L, age 32.8 years
with a weight of 77.1 kg, and 5.65 postbaseline observations
over the study), the probability of developing an ALT>ULN is
2.4%. This is substantially lower than the population mean of
6.2%, because the distribution of probabilities is skewed to
the right, and higher-risk subjects drive the average up. The
most influential covariate is a subject’s baseline ALT value
and how close it is to the ULN. Figure 1b shows that the
predicted probability of an ALT > ULN event varies from 2%
for a baseline of 20 U/L to 19% for a baseline of 40 U/L, con-
trolling for all other covariates.
To illustrate how these findings can be applied in practice
in the setting of a dose escalation study of a new investi-
gational drug, consider a hypothetical cohort of six active-
treated subjects, where we randomly chose some high ALT
values from the cohort at baseline, in order to illustrate the
substantial impact of this variable. Other baseline character-
istics were selected at random within the interquartile range.
Applying the model described above generates the probabil-
ity that each subject’s placebo twin would have had an event
(i.e., the probability that this subject would have developed
an event had he/she been receiving placebo), as shown in
the last column of Table 5.
Based on these baseline characteristics, the probability of
observing at least one ALT > ULN by chance in this cohort
of six subjects is 57%. Therefore, observing one event in this
specific cohort wouldn’t raise particular concerns about the
liver safety of the active drug:
P (at least one event) = 1 − P (zero event)
= 1 − (0.986 ∗ 0.971 ∗ 0.938 ∗ 0.843 ∗ 0.866 ∗ 0.661)
= 0.57
www.cts-journal.com
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Table 2 Raw incidence (unadjusted for study effect) of safety signals in pooled database of placebo-treated healthy volunteers
Target organ Safety event
Raw incidence (number of subjects
with at least one event /total
number of subjects) in pooled early
safety studies
Estimated incidence
rate (%)
Liver ALT > ULN 77/1,234 6.24
ALT > 2 x ULN 10/1,234 0.81
ALT > 3 x ULN 4/1,234 0.32
Bilirubin > ULN 92/1,180 7.80
Bilirubin > 2 x ULN 36/1,180 3.05
Bilirubin > 3 x ULN 30/1,180 2.54
ALT or AST > 3 x ULN; & Bilirubin > ULN 0/1,234 0
Cardiovascular systema QTcF change > 60 ms & QTcF < 500 ms 7/1,028 0.68
QTcF change > 60 ms & QTcF  500 ms 0/1,028 0
HR increase > 20 bpm 165/1,165 14.16
Standing SBP increase > 20 mmHg 64/790 8.10
Kidneyb Serum creatinine increase > 50% 0/1,234 0
Pancreas Lipase > 1.5 x ULN 34/1,125 3.02
Lipase > 3 x ULN 7/1,125 0.62
Amylase > 2 x ULN 4/1,195 0.33
ALT, alanine aminotransferase; AST, aspartate aminotransferase; QTcF, Fridericia-corrected QT interval; HR, heart rate; standing SBP, standing systolic blood
pressure (SBP) which is when blood pressure is taken when the subject is standing up. Units: ULN, upper limit of normal; bpm, beats per minute; mmHg,
millimeter of mercury.
aBaseline QTcF ranged from 347 to 481 ms, with a mean of 398.0 (SD = 12.5). Baseline HR ranged from 37 to 125 bpm, with a mean of 62.3 (SD = 10.7). Standing
SBP ranged from 86 to 168 mmHg, with a mean of 119.5 (SD = 11.9).
bBaseline serum creatinine ranged from 35 to 168 umol/L, with a mean of 81.2 (SD = 14.4). The ULN varied across studies with a median of 112 umol/L (IQR 106
to 115).
Table 3 Hypothetical situations in first-in-human studies and the corresponding probability to observe the same events under placebo
Safety event
Number of
subjects under
active drug with
an event
Rate of event
occurrence under
placebo
Probability to
observe 2/6
events under
placebo Conclusion
HR > 20 bpm from baseline 2/6 14.16% 20% Situation is not unlikely to have
happened under placebo
Amylase > 2 × ULN 1/6 0.33% 2% Situation unlikely to have
happened under placebo
The probability of at least two placebo twins experienc-
ing an ALT > ULN event is 15%. Therefore, observing
two such events on active drug in this cohort may raise
suspicions that would require further confirmation. Figure 2
illustrates the probability of observing at least 1, 2, 3, 4, 5, or
6 placebo twins with an event in this cohort.
DISCUSSION
This is the first known large review of the expected frequency
of random safety findings in placebo-treated healthy vol-
unteers. The reference event rates provided for parameters
relating to the safety of the liver, cardiovascular system,
kidney, and pancreas will provide valuable insight for clinical
teams assessing the safety of investigational compounds
in early phase studies. Using the liver enzyme ALT as an
example, we showed how predictive models can provide
a more precise assessment of the chance occurrence of a
safety signal in a subject. We developed a logistic model for
the probability of a subject developing an ALT > ULN event
during a study, while taking placebo. This model showed
that the most important factor influencing the chance of a
Table 4 Final model coefficient estimates for the logistic model of the proba-
bility of a subject experiencing an event of ALT > ULN
Model coefficientsa
Posterior
median
(log odds)
95% credible
interval
Intercept –4.16 (–4.88, –3.59)
Baseline ALT (U/L) (log transformed) 1.65 (1.30, 2.05)
Number of postbaseline samples taken 0.53 (0.22, 0.86)
Age in years (log transformed) –0.33 (–0.64, –0.03)
Weight in kg –0.31 (–0.65, –0.003)
Between-study variability (τ 2) 1.20 (0.39, 2.84)
aAll variables are standardized to a scale with a mean of 0 and a standard
deviation of 1.
random event is the ALT value at baseline. In our data set, the
mean probability estimate of a healthy volunteer to develop
an ALT > ULN event under placebo is 6.2%. For a typical
subject with average baseline characteristics (baseline ALT
value of 21.5 U/L), this probability is 2.4%. If the baseline ALT
doubles to 40 U/L, this probability increases to 19%. This
illustrates that caution should be taken when interpreting
ALT elevations in cases where the baseline value is higher
Clinical and Translational Science
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Figure 1 Model based predicted probabilities of a subject to experience an event of ALT > ULN. (a) Distribution of model-predicted
individual probabilities of ALT > ULN for all subjects in the data set. (b) Predicted probability (and interquartile range) of an ALT > ULN for
a subject depending on baseline ALT (other covariates fixed at the mean population values). For more details on how these probabilities
were calculated, see Supplementary Material.
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Figure 2 Probability of observing a given number of subjects
with an event by chance in the hypothetical cohort described by
Table 5.
than usual. Sponsors may elect to recruit only subjects with
a predicted probability of a random elevation that is lower
than 10% in FIH studies, since for those subjects it will be
easier to attribute any emerging liver safety signal to the
investigational drug. Previous attempts at quantifying the
expected incidence of ALT elevations in healthy volunteers
taking placebo3 have reported a higher ALT > ULN event
rate of 20.4%. This is probably due to the use of a small data
set and the inclusion of less healthy subjects with higher
baseline ALT levels. This highlights further the importance of
controlling for baseline when making these predictions.
There are a few limitations to this work. The first one is
the choice of modeling the ALT > ULN on a binary scale.
We first tried to model ALT on a continuous scale, as this
should theoretically make more efficient use of the data
than modeling a binary event such as ALT > ULN directly.
However, we could not find a distribution that described
the continuous data adequately (especially the tails, which
are crucial for this exercise) and a model that provided
unbiased predictions of the number of ALT > ULN events.
Another limitation is that some of the events described in the
text as “random elevations” may be partially explained by
factors that were not captured in the database. Differences
in domiciling and subject management between studies
may explain some of these differences, and unmeasured
medical history or other study-specific design features (such
as food intake, etc.) may explain others. For example, while
our database did not capture this information, we know that
most subjects in the data set were domiciled at least for the
first 3–5 days of the study and had normal access to food
three times a day. Data collection in FIH studies is likely
not optimal for this type of exercise. Each company may
have different standards for FIH protocols and the numbers
observed in studies sponsored by companies other than
Novartis may look slightly different for this reason.
Before using this database, we recommend checking that
the range of subjects’ baseline characteristics in the new
study is appropriately represented in the historical data. For
Table 5 Hypothetical cohort of active-treated subjects and individual model-based predictions for each individual’s placebo twin
Subject
Baseline ALT
(U/L) ULN (U/L)
Number of
postbaseline
samples
taken Age (years) Weight (kg)
Predicted
probability
ALT>ULN for
placebo twin
1 16 55 6 22 75 1.4%
2 21 55 6 32 78 2.9%
3 28 55 6 47 70 6.2%
4 35 55 6 25 80 15.7%
5 40 55 6 52 76 14.4%
6 50 55 6 35 77 33.9%
www.cts-journal.com
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example, if the average age in the new study is above the
99%percentile of age in the pooled database, themodel pre-
dictions may not be reliable, since they will be heavily depen-
dent on 12 subjects or less, which is <1% of the cohort.
This pooled data set should be updated annually to reflect
the most up-to-date information and these results may there-
fore change with time.
We showed that a predictive model can be used to create
“virtual placebo twins,” i.e., subjects with the same baseline
characteristics, but who would have received placebo: for
every subject experiencing an event under an investigational
drug, the model will predict the likelihood of his/her “virtual
placebo twin” experiencing the same event. The lower this
model-predicted probability, the higher the chance that
the drug under investigation is causing the issue. In early
studies, decisions are made in the context of all available
data (including preclinical evidence, pharmacokinetic data,
etc.) and this tool is not intended to lead teams to ignore
this complexity of information; rather, it should be viewed as
a way to consider one piece of the complex array of data
(namely, the rates of laboratory abnormalities) in a more
objective and quantitative way.
Finally, this work could be extended to patient popula-
tions (we think it would have particular value for rare popula-
tions, for example, pediatric studies). This would come with
additional complications, since patient studies often do not
share similar designs and inclusion criteria, unlike FIH stud-
ies of healthy volunteers. Nevertheless, we think the outcome
of this exercise could help distinguish effects related to the
drug under study from the underlying disease, in populations
where the effect of placebo has been poorly studied. In addi-
tion, this work could also be extended by using historical
placebo data from patient studies in the same or similar dis-
ease area to inform a new patient study.
By using the large amounts of placebo data collected in
healthy volunteers over decades of clinical investigations,
companies can contribute to increasing the quality of safety
decision-making in early phase clinical trials. We can quan-
tify with higher precision the expected frequency of random
safety signals in FIH studies and separate real signals from
the noise.
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